Literature DB >> 31006710

Reduced semen quality in patients with testicular cancer seminoma is associated with alterations in the expression of sperm proteins.

Tânia R Dias1,2,3, Ashok Agarwal1, Peter N Pushparaj4, Gulfam Ahmad5, Rakesh Sharma1.   

Abstract

Testicular cancer seminoma is one of the most common types of cancer among men of reproductive age. Patients with this condition usually present reduced semen quality, even before initiating cancer therapy. However, the underlying mechanisms by which testicular cancer seminoma affects male fertility are largely unknown. The aim of this study was to investigate alterations in the sperm proteome of men with seminoma undergoing sperm banking before starting cancer therapy, in comparison to healthy proven fertile men (control group). A routine semen analysis was conducted before cryopreservation of the samples (n = 15 per group). Men with seminoma showed a decrease in sperm motility (P = 0.019), total motile count (P = 0.001), concentration (P = 0.003), and total sperm count (P = 0.001). Quantitative proteomic analysis identified 393 differentially expressed proteins between the study groups. Ten proteins involved in spermatogenesis, sperm function, binding of sperm to the oocyte, and fertilization were selected for validation by western blot. We confirmed the underexpression of heat shock-related 70 kDa protein 2 (P = 0.041), ubiquinol-cytochrome C reductase core protein 2 (P = 0.026), and testis-specific sodium/potassium-transporting ATPase subunit alpha-4 (P = 0.016), as well as the overexpression of angiotensin I converting enzyme (P = 0.005) in the seminoma group. The altered expression levels of these proteins are associated with spermatogenesis dysfunction, reduced sperm kinematics and motility, failure in capacitation and fertilization. The findings of this study may explain the decrease in the fertilizing ability of men with seminoma before starting cancer therapy.

Entities:  

Keywords:  male fertility; proteomics; seminoma; sperm proteins; sperm quality; testicular cancer

Year:  2020        PMID: 31006710      PMCID: PMC6958970          DOI: 10.4103/aja.aja_17_19

Source DB:  PubMed          Journal:  Asian J Androl        ISSN: 1008-682X            Impact factor:   3.285


INTRODUCTION

Germ cell tumors (GCTs) represent the most common type of testicular cancer, accounting for about 90%–95% of all cases. The principal types of GCTs are nonseminomas and seminomas; the latter usually grows and spreads more slowly. In the last decades, there is a growing trend in the proportion of seminomas.1 The survival rate of men with seminoma is very high (over 95%); thus, it is generally not seen as a threat to public health. However, its impact on male fertility represents a major concern for reproductive medicine as it frequently affects men in reproductive age (20–44 years).2 Men with seminoma present impaired fertilizing ability, even before diagnosis.3 Testicular cancer seminoma affects the hypothalamic-pituitary-gonadal (HPG) axis and consequently disturbs spermatogenesis.4 These deleterious effects are dependent on the stage and type of seminoma, resulting in poor semen quality or even azoospermia.5 The treatment for this type of cancer, usually performed by surgery, chemotherapy, or radiotherapy, further affects semen quality5 and hormonal function,6 thus highly impairing male fertility. In fact, after cancer therapy, patients may become temporarily or permanently infertile.7 For that reason, it is strongly recommended that men diagnosed with seminoma undergo sperm banking to increase the probability to father a child in the future.8 The chances to establish a pregnancy by natural conception are 30% lower after the cancer therapy and the recovery of fertilizing ability usually takes several years.9 Therefore, in many surviving patients with seminoma, assisted reproductive technology (ART) with cryopreserved samples is the only option for having children.10 Still, sperm banking is not possible for many patients due to the high cost or lack of facilities, urgency to initiate the treatment, impaired spermatogenesis, and/or poor semen quality at the time of specimen collection.11 Proteomics studies have been recently used as a valuable tool to explore how certain health conditions affect male reproductive potential, especially by evaluating spermatozoa and seminal plasma proteome.1213 Although spermatozoa are transcriptionally and translationally silent after being produced in the testis, the acquisition of sperm function occurs during maturation in the epididymis and transit through the female reproductive tract.14 Therefore, the sperm proteome is highly susceptible to alterations according to the health status of the individual, and this impacts the quality of sperm parameters. The deleterious effects of seminoma treatment represent a challenge to understand the mechanisms behind the impairment of male fertility caused by the disease. In this study, we used semen samples from men with testicular cancer seminoma that were cryopreserved before starting cancer therapy, to investigate alterations in the sperm proteome in comparison with healthy proven fertile men.

PARTICIPANTS AND METHODS

Semen analysis and cryopreservation

This study was conducted after approval by the Institutional Review Board (IRB) of Cleveland Clinic, Cleveland, OH, USA. Semen samples were obtained from healthy volunteers with proven fertility (control, n = 15) and patients with seminoma (n = 15). All the participants signed informed written consent to allow the use of their samples in this study. The inclusion criteria were as follows: (1) control group, healthy fertile men who had fathered a child in the last 2 years; (2) seminoma group, patients diagnosed with seminoma and undergoing sperm banking before starting cancer therapy. Following 2–3 days of abstinence, semen samples were collected at the Andrology Center, Cleveland Clinic. Samples were liquefied for 20–30 min in an incubator (Panasonic, Newark, NJ, USA) at 37°C, and a routine semen analysis was conducted according to the World Health Organization (WHO) 2010 guidelines.15 Semen volume, sperm motility, and sperm concentration were recorded. Total sperm count and total motile count were also calculated and the results were expressed as mean ± standard error of the mean (s.e.m.). Whole ejaculate samples were immediately cryopreserved in TEST-yolk buffer (TYB; Irvine Scientific, Santa Ana, CA, USA) in a ratio of 1:1 as previously described16 and finally labeled and stored in liquid nitrogen at −196°C.

Protein extraction and estimation

Samples were thawed on ice and centrifuged at 4000g for 10 min (Eppendorf, Hauppauge, NY, USA). To remove the freezing medium (TYB) as much as possible, the sperm pellet was washed four times in phosphate-buffered saline (PBS; Sigma-Aldrich, St. Louis, MO, USA) and centrifuged at 4000g for 10 min at 4°C. Total sperm protein was extracted overnight at 4°C with radioimmunoprecipitation assay (RIPA) buffer (Sigma-Aldrich). Subsequently, samples were centrifuged at 10 000g for 30 min at 4°C, to recover the protein fraction (supernatant). Pierce BCA Protein Assay kit (Thermo Fisher Scientific, Waltham, MA, USA) was used to estimate the protein concentration, according to the manufacturer's instructions.

Quantitative proteomic analysis

Three samples from the control or seminoma group were randomly selected for the proteomic analysis by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Samples were pooled (n = 3) using the same amount of protein from each sample. Each pool was then evaluated as an individual sample in the proteomic analysis. The system used was a Finnigan LTQ-Orbitrap Elite hybrid mass spectrometer (Thermo Fisher Scientific) using the previously described conditions and software.17 Scaffold (version 4.0.6.1, Proteome Software Inc., Portland, OR, USA) was used for the identification of differentially expressed proteins (DEPs) between the control and seminoma groups. The spectral counts were used to determine the abundance of each protein (very low, low, medium, or high). The identified DEPs were categorized as underexpressed, overexpressed, or unique to one of the groups, based on the normalized spectral abundance factor (NSAF) ratio according to previously reported criteria.17

Bioinformatic analysis

Bioinformatic analysis of DEPs identified by LC-MS/MS was carried out using the Ingenuity Pathway Analysis software (IPA; Qiagen, Hilden, Germany). IPA was used to evaluate the canonical pathways, top diseases and bio-functions, and upstream regulators related to the identified DEPs. Proteins were selected for validation by western blot considering the following criteria: (1) proteins involved in reproductive system development and function; (2) proteins involved in the top canonical pathways; (3) proteins with a higher difference of abundance between the experimental groups; and (4) proteins with a well-described function in the literature. Only proteins that met all the above-mentioned criteria were subjected to western blot.

Western blot

Western blot was performed using individual samples from the control and seminoma groups (n = 6 per group). A total of 25 μg protein per sample was mixed with 4 × Laemmli sample buffer (Bio-Rad, Hercules, CA, USA) in a ratio of 1:3 and made up to 25 μl with PBS. Samples were boiled at 95°C for 10 min and immediately loaded into a 4%–15% (w/v) polyacrylamide gel (Bio-Rad). Electrophoresis was performed with constant voltage (90 V) for 2 h. Precision Plus Protein™ Dual Xtra Standard (Thermo Fisher Scientific) was used as the molecular weight marker. The resolved proteins were transferred (20 V for 30 min) to methanol-activated polyvinylidene difluoride (PVDF) membranes (GE Healthcare, Marlborough, MA, USA) and blocked for 90 min at room temperature, with a 5% (w/v) nonfat milk (Bio-Rad) solution prepared in tris-buffered saline with tween-20 (TBST; Sigma-Aldrich). Membranes were incubated overnight (4°C) with specific primary antibodies followed by the respective secondary antibodies at room temperature, for 90 min (). Membranes were incubated with enhanced chemiluminescence (ECL) reagent (GE Healthcare) for 5 min, and the chemiluminescence signals were read in the ChemiDoc™ MP Imaging System (Bio-Rad). Densities from each band were quantified with Image Lab™ Software (version 6.0.1, Bio-Rad) and divided by the corresponding total protein lane density. Total protein density was obtained by incubation of the membranes with total colloidal gold protein stain (BioRad). The results were expressed as fold variation relative to the control group. List of the primary and secondary antibodies used in this study *Secondary antibody. ACE: angiotensin-converting enzyme; ACR: acrosin precursor; CCT3: T-complex protein 1 subunit gamma; SPA17: sperm surface protein Sp17; ATP1A4: sodium/potassium-transporting ATPase subunit alpha-4; HSPA2: heat shock-related 70 kDa protein 2; PSME4: proteasome activator complex subunit 4; NDUFS1: NADH-ubiquinone oxidoreductase 75 kDa subunit; UQCRC2: cytochrome b-c1 complex subunit 2; ATP5A: ATP synthase subunit alpha

Statistical analyses

After testing normal distribution by the Kolmogorov–Smirnov test, semen parameters and western blot results were analyzed by Mann–Whitney U test for independent samples, using the MedCalc Software (version 17.8; MedCalc Software, Ostend, Belgium). All data are presented as mean ± s.e.m., and differences with P < 0.05 were considered statistically significant.

RESULTS

Semen quality in patients with testicular cancer seminoma

The average volume of the ejaculates was very similar between the control and seminoma groups (). However, there was a decrease in sperm motility (P = 0.019), sperm concentration (P = 0.003), total sperm count (P = 0.001), and total motile count (P = 0.001) in patients with seminoma relative to control (). Nevertheless, all the samples were considered normozoospermic according to the WHO 2010 criteria.15 Semen parameters of fertile men (control) and patients with testicular cancer seminoma Results are presented as mean±s.e.m. (n=15 per group). Statistical significance was considered for P < 0.05. s.e.m.: standard error of the mean

Differentially expressed proteins

Proteomic analysis identified 1149 proteins in the control group and 911 in the seminoma group. After comparative analysis between the experimental groups, a total of 1192 proteins were quantified and 393 were found to be differentially expressed (). More than half (52.7%) of the DEPs were underexpressed, while 20.1% were overexpressed in spermatozoa of patients with seminoma. Furthermore, 4.1% of the DEPs were unique to the seminoma group and 23.1% unique to the control group (). List of the differentially expressed proteins identified by the bioinformatic analysis when comparing the sperm proteome of fertile men (control) and patients with testicular cancer seminoma H: high; L: low; M: medium; ni: not identified; NSAF: normalized spectral abundance factor; OE: overexpressed; SC: spectral counts; UE: underexpressed; VL: very low Number of proteins identified by proteomic analysis of spermatozoa samples obtained from fertile men (control) and men with testicular cancer seminoma, and expression profile of the DEPs identified after comparative analysis between the experimental groups. DEPs: differentially expressed proteins.

Selection of proteins for validation

According to the IPA analysis, among the top diseases and bio-functions related to “physiological system development and function,” the category with the highest P value was “reproductive system development and function.” Within this category, we selected seven proteins involved in specific reproductive processes (): angiotensin-converting enzyme (ACE), acrosin precursor (ACR), T-complex protein 1 subunit gamma (CCT3), sperm surface protein Sp17 (SPA17), sodium/potassium-transporting ATPase subunit alpha-4 (ATP1A4), heat shock-related 70 kDa protein 2 (HSPA2), and proteasome activator complex subunit 4 (PSME4). Some of these proteins were also involved in the top canonical pathways identified in this dataset. While HSPA2 participates in the “protein ubiquitination pathway” and “unfolded protein response,” ACE is related to “phagosome maturation.” Other top five canonical pathways included “mitochondrial dysfunction” and “oxidative phosphorylation.” Among the proteins involved in those pathways were NADH-ubiquinone oxidoreductase 75 kDa subunit (NDUFS1), cytochrome b-c1 complex subunit 2 (UQCRC2), and ATP synthase subunit alpha (ATP5A), which are subunits of the mitochondrial complexes I, III, and V, respectively. These three proteins were also selected for analysis by western blot. The abundance and expression pattern of the ten selected proteins obtained by the proteomic analysis is presented in . Specific functions of the differentially expressed proteins related to reproductive system development and function identified by the bioinformatic analysis when comparing the sperm proteome of patients with testicular cancer seminoma with fertile men ACE: angiotensin-converting enzyme; ACR: acrosin precursor; ATP1A4: sodium/potassium-transporting ATPase subunit alpha-4; CCT3: T-complex protein 1 subunit gamma; HSPA2: heat shock-related 70 kDa protein 2; PSME4: proteasome activator complex subunit 4; SPA17: sperm surface protein Sp17 Proteomic data of the differentially expressed proteins identified in the spermatozoa samples of fertile men (control) and men with testicular cancer seminoma before cancer therapy, which were selected for validation by western blot ACE: angiotensin-converting enzyme; ACR: acrosin; ATP1A4: sodium/potassium-transporting ATPase subunit alpha-4; ATP5A: ATP synthase subunit alpha; CCT3: T-complex protein 1 subunit gamma; HSPA2: heat shock-related 70 kDa protein 2; NDUFS1: NADH-ubiquinone oxidoreductase 75 kDa subunit; NSAF: normalized spectral abundance factor; PSME4: proteasome activator complex subunit 4; SPA17: sperm surface protein Sp17; UQCRC2: cytochrome b-c1 complex subunit 2

Prediction of the upstream regulators

The IPA analysis predicted the activation or inhibition of several proteins, which could be responsible for the altered expression in the sperm proteome of men with seminoma. The rapamycin-insensitive companion of mammalian target of rapamycin (RICTOR) was predicted to be activated, thus leading to the underexpression of NDUFS1, UQCRC2, ATP5A1, and PSME4. Moreover, it was predicted that the underexpression of ATP5A1 and ATP1A4 may involve the activation of the amyloid-beta A4 protein (APP). On the other hand, the inhibition of the heat shock factor protein 2 (HSF2) was predicted to regulate the underexpression of CCT3, as well as six other chaperonins of the T-complex protein-1 (TCP-1) family (CCT2, CCT4, CCT5, CCT6A, CCT7, and CCT8).

Western blot analysis

All proteins selected for western blot analysis were identified. There was an increase in the protein expression of ACE (P = 0.005) and ACR (P = 0.009) in the seminoma group (2.61 ± 0.38 and 2.02 ± 0.26-fold variation to control, respectively) in comparison with the control (1.00 ± 0.25 and 1.00 ± 0.19, respectively) (). On the other hand, there was a decrease in the protein levels of ATP1A4 (P = 0.016) and HSPA2 (P = 0.041) in men with seminoma (0.53 ± 0.03 and 0.32 ± 0.11-fold variation to control, respectively) when compared with the control group (1.00 ± 0.25 and 1.00 ± 0.22, respectively) (). The protein levels of CCT3, SPA17, and PSME4 were similar between the study groups. There was also a decrease (P = 0.026) in the protein expression levels of UQCRC2 (0.34 ± 0.14-fold variation to control) in the seminoma group relative to the control (1.00 ± 0.14) (). No differences were found in the protein levels of NDUFS1 or ATP5A1 between the experimental groups. Graphical representation of the expression levels of proteins involved in reproductive functions (ACE, ACR, ATP1A4, CCT3, HSPA2, PSME4, and SPA17) in spermatozoa samples obtained from fertile men (control) and men with testicular cancer seminoma. Results are presented as fold variation to control and expressed as mean±standard error of the mean (n = 15 per group). Statistical significance is indicated as: *P < 0.05, **P < 0.01, seminoma versus control. Representative blots for each protein are also presented. ACE: angiotensin-converting enzyme; ACR: acrosin precursor; ATP1A4: sodium/potassium-transporting ATPase subunit alpha-4; CCT3: T-complex protein 1 subunit gamma; HSPA2: heat shock-related 70 kDa protein 2; PSME4: proteasome activator complex subunit 4; SPA17: sperm surface protein Sp17. Graphical representation of the protein expression levels of mitochondrial complex subunits NDUFS1, UQCRC2, and ATP5A1 in spermatozoa samples obtained from fertile men (control) and men with testicular cancer seminoma. Results are presented as fold variation to control and expressed as mean ± standard error of the mean (n = 15 per group). Statistical significance is indicated as: *P < 0.05, seminoma versus control. Representative blots for each protein are also presented. NDUFS1: NADH-ubiquinone oxidoreductase 75 kDa subunit; UQCRC2: cytochrome b-c1 complex subunit 2; ATP5A: ATP synthase subunit alpha.

DISCUSSION

The present study is the first attempt to identify alterations in spermatozoa proteome of patients with seminoma before initiating cancer therapy, using fertile donors as control group. Our goal was to evaluate the expression levels of proteins involved in reproductive function from spermatogenesis to sperm function and fertilization. This may provide new insights on the underlying mechanisms responsible for the reduced sperm quality in men with seminoma. Spermatogenesis consists of a complex process of spermatozoa production that involves several steps of germ cell differentiation. The bioinformatic analysis identified an underexpression of PSME4 in spermatozoa of patients with seminoma. PSME4 plays a role in the morphology of male germ cells; it is particularly important for histone replacement during chromatin remodeling and DNA double-strand break repair.18 It has been reported that mice lacking this protein present impaired spermatogenesis and reduced fertility.19 Thus, the downregulation of this protein may contribute to reduced fertility in men with seminoma. Although we were not able to confirm the underexpression of PSME4 by western blot in our dataset, we observed the underexpression of the molecular chaperone HSPA2 by both proteomics and western blot analysis. Molecular chaperones are essential for normal sperm production and functional transformation. HSPA2 acts as a protein quality control system as it ensures the correct folding/refolding of proteins and activates the degradation of misfolded proteins.20 It has been described that HSPA2 participates in the stability of the microtubules during the meiotic process of germ cell differentiation.21 In fact, animal studies show that knockout mice for Hspa2 exhibit an enormous number of apoptotic germ cells, resulting in infertility.22 Men with abnormal spermatogenesis frequently present a reduced hspA2 mRNA expression.23 Thus, the downregulation of HSPA2 protein in men with seminoma may contribute to the decreased production of normal spermatozoa during spermatogenesis, which is in accordance with the observed reduction in sperm concentration and total sperm count in seminoma group. The protein ATP1A4 was identified as downregulated in seminoma group by the proteomic analysis, and this result was confirmed by the western blot technique. IPA analysis revealed that ATP1A4 participates in several reproductive processes, including spermatogenesis, function of sperm, cell movement of sperm, hyperactivation, and fertilization. ATP1A4 is the catalytic subunit of the Na+/K+-ATPase membrane protein, which controls the exchange of sodium and potassium ions across the plasma membrane in an ATP-dependent reaction.24 The regulation of ions in spermatozoa is essential for the acquisition of motility and fertilizing ability. ATP1A4 plays a key role in maintaining human sperm motility.25 It has been shown that male mice lacking this subunit are completely sterile and their spermatozoa present not only reduced motility but also impaired hyperactivation and inability to fertilize in vitro.26 These studies highlight the importance of ATP1A4 for male fertility, and the underexpression of this protein in spermatozoa of men with seminoma may explain the decrease in sperm motility and total motile count relative to proven fertile men (control group). The downregulation of ATP1A4 was related to the activation of APP. In fact, this protein has been identified in human spermatozoa and suggested to play an important role in sperm function, especially in signaling events involved in sperm motility.27 Another important process crucial for sperm function is mitochondrial function. It is required for energy production necessary for spermatozoa movement and production of reactive oxygen species (ROS) in physiological amounts to trigger capacitation and regulate hyperactivation and acrosome reaction.28 Mitochondrial function relies on the expression of the mitochondrial complexes I–IV for oxidative phosphorylation (OXPHOS) and complex V for ATP production.29 Our proteomic data showed a downregulation of NDUFS1, UQCRC2, and ATP5A1 in the seminoma group, which are subunits of complex I, III, and V, respectively. The downregulation of these three proteins was predicted to be induced by the activation of RICTOR, which plays a key role in spermatogenesis and sperm maturation signaling pathways.28 The mitochondrial subunits are essential for the proper assembly of the complexes; thus, alterations in their protein expression in spermatozoa are indicative of mitochondrial dysfunction, as reported by the IPA canonical pathways.30 Although the western blot analysis demonstrated a tendency of reduced expression of the three mitochondrial subunits, only the UQCRC2 was decreased in patients with seminoma. Downregulation of UQCRC2 was associated with reduced sperm kinematics, ATP production, and capacitation, which ultimately compromises sperm binding and fertilization.31 In fact, an underexpression of UQCRC2 was observed in infertile men with varicocele.32 The acquisition of sperm fertilizing ability involves a timed triggering of events in the female reproductive system, culminating in sperm–oocyte binding. SPA17 and CCT3 are two sperm proteins involved in this function, which were identified as downregulated in the seminoma group by the proteomic analysis. SPA17 is a mannose-binding protein that binds to zona pellucida carbohydrates during fertilization.33 It also plays an important role in germ cell differentiation during spermatogenesis, as its expression increases from early to late stages.34 CCT3 is one of the subunits of the TCP-1 complex. Although we selected to evaluate the expression levels of this subunit, six other subunits of this complex (CCT2, CCT4, CCT5, CCT6A, CCT7, and CCT8) were also downregulated in men with seminoma. These subunits mediate capacitation-dependent binding of spermatozoa to the zona pellucida.35 Thus, the downregulation of this system may compromise sperm fertilization.36 The downregulation of TCP-1 complex subunits was predicted to be due to HSF2 inhibition. In fact, disruption of hsf2 in mice affected testicular size37 and induced spermatogenic defects.38 When active, HSF2 is likely to induce the upregulation of HSPA2.39 Thus, the predicted inhibition of HSF2 in men with seminoma is in accordance with the downregulation of HSPA2. Although the underexpression of SPA17 and CCT3 was not confirmed by the western blot, the downregulation of HSPA2 in men with seminoma may contribute to the loss of sperm function. In fact, this protein is known to regulate the formation of zona pellucida-binding sites in spermatozoa during spermatogenesis.40 In addition, it regulates fertilization by mediating the function of sperm surface receptors, such as sperm adhesion molecule 1 (SPAM1) and arylsulfatase A (ARSA), during sperm-egg recognition.41 Previous proteomic studies have shown low expression levels of HSPA2 in men with asthenozoospermia42 and primary or secondary infertility.43 Another study also reported a downregulation of HSPA2, ATP1A4, and SPA17 in infertile varicocele patients.32 Our results suggest that the altered expression levels of these proteins in men with seminoma may contribute to the impairment of male fertility. The proteomic analysis also identified ACE as overexpressed in the seminoma group, and this result was confirmed by western blot. This protein is a zinc metallopeptidase responsible for the conversion of angiotensin I to angiotensin II.44 The role of ACE in male reproductive function is not completely understood. Studies with ACE-deficient mice reported that these animals produce a normal number of spermatozoa and present normal motility and morphology. However, the spermatozoa were unable to bind and fertilize the egg.4546 A negative correlation between sperm-bound ACE activity and sperm motility has also been observed.47 The testis-specific isoform of this protein (tACE) is believed to be released from functional spermatozoa during capacitation and acrosome reaction to increase the fertilizing ability.48 In fact, a lower tACE activity was detected in spermatozoa from normozoospermic men relative to those with oligoasthenozoospermia.47 Thus, the overexpression of this protein in spermatozoa from men with seminoma may be responsible for the decrease in sperm motility observed in this group, and possibly explains why some men with seminoma are not able to have children even before the treatment. Finally, the protein ACR, in its precursor form (proacrosin), was identified as underexpressed in the seminoma group by the proteomic analysis. This protein is activated and converted to its active form during acrosome reaction, playing a role in sperm–oocyte binding.49 In contrast, using western blot, we found a high overexpression of this protein in men with seminoma. Although we cannot clearly infer about the molecular mechanisms, any of the scenarios (underexpression/overexpression) could lead to a defective acrosome reaction and impaired fertilization. The difference on these results may be due to the sensitivity of each technique and to the sample size. Further studies to assess acrosin activity in men with seminoma are needed to clarify the impact of this condition in acrosome reaction. Overall, our study points toward important alterations in sperm proteins with a key role in male fertility in men with seminoma. As of today, no specific sperm markers have been identified for the clinical diagnosis and monitoring of testicular cancer seminoma development. The expression levels of HSPA2, ATP1A4, UQCRC2, and ACE can be helpful sperm biomarkers when evaluating the fertility status of a man, which may allow the early diagnosis of seminomas in a noninvasive approach. Although there is still a lot to explore in the pathophysiology of male subfertility/infertility in men with seminoma, our results represent a step forward in understanding the molecular mechanisms behind the reduced sperm quality in these patients. Future advances in mass spectrometry and bioinformatics will improve our understanding on human sperm function in healthy and disease conditions.

AUTHOR CONTRIBUTIONS

AA and RS were responsible for the conception and design of the study. TRD was responsible for the acquisition and interpretation of data, as well as writing the first draft. GA helped in samples processing and PNP performed the bioinformatic analysis. All authors read and approved the final manuscript.

COMPETING INTERESTS

All authors declared no competing interests.
Supplementary Table 1

List of the primary and secondary antibodies used in this study

AntibodySourceKDaDilutionVendorCatalog Number
ACERabbit2001:1000Abcamab85955
ACRRabbit461:1000Abcamab203289
ATP1A4Rabbit1001:10000Abcamab76020
ATP5AMouse541:1000Abcamab110411
CCT3Rabbit611:2000Abcamab225878
HSPA2Mouse701:500Abcamab89130
NDUFS1Rabbit791:10000Abcamab157221
PSME4Rabbit2111:500Abcamab181203
SPA17Rabbit171:1000Abcamab172626
UQCRC2Mouse481:1000Abcamab110411
Mouse*Rabbit-1:10000Abcamab6728
Rabbit*Goat-1:10000Abcamab97051

*Secondary antibody. ACE: angiotensin-converting enzyme; ACR: acrosin precursor; CCT3: T-complex protein 1 subunit gamma; SPA17: sperm surface protein Sp17; ATP1A4: sodium/potassium-transporting ATPase subunit alpha-4; HSPA2: heat shock-related 70 kDa protein 2; PSME4: proteasome activator complex subunit 4; NDUFS1: NADH-ubiquinone oxidoreductase 75 kDa subunit; UQCRC2: cytochrome b-c1 complex subunit 2; ATP5A: ATP synthase subunit alpha

Table 1

Semen parameters of fertile men (control) and patients with testicular cancer seminoma

ParameterControlSeminomaP
Semen volume (ml)3.53±0.353.33±0.420.541
Sperm motility (%)67±354±50.019
Sperm concentration (106 ml−1)95.49±7.7946.72±12.190.003
Total sperm count (106)316.92±45.41136.11±41.550.001
Total motile count (106)211.88±30.0975.63±22.440.001

Results are presented as mean±s.e.m. (n=15 per group). Statistical significance was considered for P < 0.05. s.e.m.: standard error of the mean

Supplementary Table 2

List of the differentially expressed proteins identified by the bioinformatic analysis when comparing the sperm proteome of fertile men (control) and patients with testicular cancer seminoma

ProteinAccessionAverage SCAbundanceNSAF ratiot-testExpression



ControlSeminomaControlSeminomaSeminoma/ControlP
1Transmembrane and coiled-coil domain-containing protein 25684761023.30Mni0.000.00000Unique to Control
2Isocitrate dehydrogenase (NAD) subunit alpha, mitochondrial precursor503177748.00Mni0.000.00000Unique to Control
3Succinyl-CoA ligase (ADP-forming) subunit beta, mitochondrial precursor1132158325.70Mni0.000.00001Unique to Control
4Short-chain specific acyl-CoA dehydrogenase, mitochondrial precursor455723350.00Mni0.000.00001Unique to Control
5Probable serine carboxypeptidase CPVL isoform X153038484827.00Mni0.000.00006Unique to Control
6ATP synthase subunit O, mitochondrial precursor450230333.70Mni0.000.00018Unique to Control
7Doublecortin domain-containing protein 2C56600616621.70Mni0.000.00021Unique to Control
8Bifunctional glutamate/proline-tRNA ligase6224104221.00Mni0.000.00088Unique to Control
9Exportin-715444889227.30Mni0.000.00197Unique to Control
10Uncharacterized protein KIAA1683 isoform X153041521623.30Mni0.000.00606Unique to Control
11Leucine-rich repeat-containing protein 37A3 isoform X1457884021812.30Lni0.000.00000Unique to Control
12Heme oxygenase 2 isoform a55594391811.30Lni0.000.00001Unique to Control
13Actin-related protein T322113971417.70Lni0.000.00001Unique to Control
14Ubiquitin carboxyl-terminal hydrolase 7 isoform 115037853318.30Lni0.000.00001Unique to Control
15Tetratricopeptide repeat protein 251389923312.70Lni0.000.00003Unique to Control
16Actin-like protein 7A572972016.70Lni0.000.00005Unique to Control
17Dynein intermediate chain 2, axonemal isoform X453041267015.70Lni0.000.00008Unique to Control
18Four and a half LIM domains protein 1 isoform 522848020518.70Lni0.000.00008Unique to Control
19Putative lipoyltransferase 2, mitochondrial precursor2215545209.00Lni0.000.00011Unique to Control
20Tubulin polymerization-promoting protein family member 222649135016.30Lni0.000.00012Unique to Control
21Isocitrate dehydrogenase (NAD) subunit beta, mitochondrial isoform a precursor2817882119.30Lni0.000.00019Unique to Control
22Protein DPCD3993035518.30Lni0.000.00028Unique to Control
23Long-chain-fatty-acid-CoA ligase 3427947549.70Lni0.000.00031Unique to Control
24Sodium/potassium-transporting ATPase subunit alpha-3 isoform 12274866717.30Lni0.000.00047Unique to Control
2526S proteasome non-ATPase regulatory subunit 452921619.00Lni0.000.00047Unique to Control
26ATP synthase subunit g, mitochondrial514791569.00Lni0.000.00049Unique to Control
27Acyl-CoA dehydrogenase family member 9, mitochondrial2136149718.00Lni0.000.00061Unique to Control
28Transcription factor A, mitochondrial isoform 1 precursor450740115.00Lni0.000.00065Unique to Control
29Elongation factor Tu, mitochondrial precursor3414763010.70Lni0.000.00066Unique to Control
30Eukaryotic translation elongation factor 1 epsilon-1 isoform 22088794708.00Lni0.000.00068Unique to Control
31Voltage-dependent calcium channel subunit alpha-2/delta-2 isoform X15303733858.00Lni0.000.00075Unique to Control
32Armadillo repeat-containing protein 12 isoform X153038160312.00Lni0.000.00079Unique to Control
33Deoxyuridine 5’- triphosphate nucleotidohydrolase, mitochondrial isoform 37090644413.00Lni0.000.00081Unique to Control
34Probable inactive serine protease 37 isoform 1 precursor2853941649.00Lni0.000.00087Unique to Control
3526S proteasome non-ATPase regulatory subunit 1450319819.00Lni0.000.00088Unique to Control
36Mitochondria-eating protein isoform X453037673616.70Lni0.000.00097Unique to Control
37Mitochondrial fission 1 protein1511084738.70Lni0.000.00110Unique to Control
38Alpha-soluble NSF attachment protein479333798.00Lni0.000.00137Unique to Control
39Maleylacetoacetate isomerase isoform 1222026249.00Lni0.000.00179Unique to Control
4040S ribosomal protein S15450668710.00Lni0.000.00184Unique to Control
41Aladin isoform 22910453078.30Lni0.000.00186Unique to Control
42Ubiquitin carboxyl-terminal hydrolase isozyme L12136109114.30Lni0.000.00195Unique to Control
43Stomatin-like protein 2, mitochondrial isoform a730550312.30Lni0.000.00200Unique to Control
44Protein FAM209B isoform X25788359928.00Lni0.000.00205Unique to Control
45Putative protein FAM71E222397270412.30Lni0.000.00229Unique to Control
46Acyl-protein thioesterase 1 isoform 1545372211.70Lni0.000.00240Unique to Control
47Histone H1t205441688.00Lni0.000.00244Unique to Control
48Armadillo repeat-containing protein 4 isoform X357881843018.70Lni0.000.00324Unique to Control
49Dnaj homolog subfamily B member 1 isoform X157883321013.30Lni0.000.00375Unique to Control
50Calcium-binding mitochondrial carrier protein Aralar2 isoform 123764901914.00Lni0.000.00450Unique to Control
51Long-chain-fatty-acid-CoA ligase ACSBG2 isoform a57458455717.70Lni0.000.00479Unique to Control
52Methionine-tRNA ligase, cytoplasmic1404302210.00Lni0.000.00512Unique to Control
5360S acidic ribosomal protein P0450666713.30Lni0.000.00722Unique to Control
54Cytoplasmic dynein 1 heavy chain 13335093211.30Lni0.000.00728Unique to Control
55ADP-ribosylation factor 645022119.00Lni0.000.00763Unique to Control
56Glycine-tRNA ligase precursor11680534015.00Lni0.000.00770Unique to Control
57BAG family molecular chaperone regulator 5 isoform b66310779.30Lni0.000.00818Unique to Control
5860S ribosomal protein L7a45066615.30VLni0.000.00000Unique to Control
59Isobutyryl-CoA dehydrogenase, mitochondrial76568497.00VLni0.000.00000Unique to Control
60cAMP-dependent protein kinase catalytic subunit gamma156190157.00VLni0.000.00000Unique to Control
61Vitamin K epoxide reductase complex subunit 1-like protein 1 isoform 1463094633.70VLni0.000.00000Unique to Control
62Translocation protein SEC63 homolog60058722.00VLni0.000.00001Unique to Control
63UDP-N-acetylhexosamine pyrophosphorylase1566275753.00VLni0.000.00001Unique to Control
64Guanine nucleotide-binding protein subunit beta-2-like 151744472.00VLni0.000.00003Unique to Control
65Dynein intermediate chain 1, axonemal isoform 25264798307.00VLni0.000.00003Unique to Control
66Fibronectin type III domain-containing protein 889221382.00VLni0.000.00009Unique to Control
6740S ribosomal protein S26-like5304387023.00VLni0.000.00009Unique to Control
68Mitochondrial import receptor subunit TOM22 homolog99103826.00VLni0.000.00009Unique to Control
69Cation channel sperm-associated protein subunit beta precursor513392952.00VLni0.000.00009Unique to Control
70Maestro heat-like repeat-containing protein family member 72232784103.30VLni0.000.00010Unique to Control
71ADP-ribosylation factor-like protein 2 isoform 11486128852.70VLni0.000.00015Unique to Control
72protein NDRG1 isoform 12070287484.00VLni0.000.00016Unique to Control
73Speriolin isoform 11972766686.30VLni0.000.00017Unique to Control
74Radial spoke head protein 6 homolog A135405593.30VLni0.000.00018Unique to Control
75DCN1-like protein 1360308834.70VLni0.000.00025Unique to Control
76dnaJ homolog subfamily C member 3 precursor54539803.70VLni0.000.00025Unique to Control
77Sialic acid synthase120564733.00VLni0.000.00028Unique to Control
78Glutamine-tRNA ligase isoform b4414783053.70VLni0.000.00028Unique to Control
79Mimitin, mitochondrial297894094.30VLni0.000.00031Unique to Control
8060S ribosomal protein L22 proprotein45066135.00VLni0.000.00032Unique to Control
81EF-hand calcium-binding domain-containing protein 1476621606.70VLni0.000.00033Unique to Control
82Iron-sulfur cluster assembly enzyme ISCU, mitochondrial isoform X15304000134.70VLni0.000.00036Unique to Control
83Growth hormone-inducible transmembrane protein1182003564.70VLni0.000.00037Unique to Control
84S-phase kinase-associated protein 1 isoform b257777134.00VLni0.000.00040Unique to Control
85Calcium-binding mitochondrial carrier protein Aralar1213611033.30VLni0.000.00050Unique to Control
86diphosphomevalonate decarboxylase45052892.30VLni0.000.00051Unique to Control
87V-type proton ATPase subunit E 2 isoform X15303682604.00VLni0.000.00052Unique to Control
88Nucleosome assembly protein 1-like 1213277084.30VLni0.000.00056Unique to Control
8926S protease regulatory subunit 4244301516.00VLni0.000.00056Unique to Control
90Mitochondrial ornithine transporter 176575855.30VLni0.000.00057Unique to Control
9160S ribosomal protein L5145919093.70VLni0.000.00097Unique to Control
92Dynein heavy chain 17, axonemal25654231088.01.0HVL0.010.00001UE in Seminoma
93L-amino-acid oxidase isoform 2 precursor38438147576.00.3MVL0.010.00000UE in Seminoma
94Sperm-associated antigen 6 isoform X153039255258.00.3MVL0.010.00000UE in Seminoma
95Nuclear pore complex protein Nup93 isoform X153042455937.70.3MVL0.010.00129UE in Seminoma
96Valine-tRNA ligase545415887.71.7HVL0.010.00004UE in Seminoma
97Sperm surface protein Sp17839434331.30.3MVL0.020.00010UE in Seminoma
98Exportin-2 isoform 12902955916.70.3LVL0.020.00026UE in Seminoma
9926S proteasome non-ATPase regulatory subunit 13 isoform 115750219319.70.3LVL0.020.00142UE in Seminoma
100Cathepsin F precursor604219621.00.3MVL0.030.00007UE in Seminoma
10126S proteasome non-ATPase regulatory subunit 72577761513.70.3LVL0.030.00230UE in Seminoma
102Uncharacterized protein C7orf615197222614.30.3LVL0.030.00109UE in Seminoma
103Vacuolar protein sorting-associated protein 13A isoform C6634667219.70.3LVL0.030.00122UE in Seminoma
104Mitochondrial pyruvate carrier 1-like protein30692239618.00.3LVL0.030.00012UE in Seminoma
105Plasma membrane calcium-transporting ATPase 4 isoform 4b4825595752.32.7MVL0.030.00001UE in Seminoma
106Presequence protease, mitochondrial isoform 2 precursor4135206150.31.0MVL0.030.00003UE in Seminoma
107Exportin-1 isoform X15303680708.30.3LVL0.030.00004UE in Seminoma
108Ras-related protein Rab-11B19035851715.70.3LVL0.030.00012UE in Seminoma
109Phosphatidylethanolamine-binding protein 4 precursor11681262215.00.3LVL0.040.00029UE in Seminoma
110Protein FAM71A28272109412.30.3LVL0.040.00258UE in Seminoma
111Puromycin-sensitive aminopeptidase15893723645.01.3MVL0.040.00124UE in Seminoma
112Epimerase family protein SDR39U1 isoform 111681263013.30.3LVL0.040.00151UE in Seminoma
113V-type proton ATPase catalytic subunit A1991342415.70.3LVL0.040.00313UE in Seminoma
114Cullin-associated NEDD8-dissociated protein 121361794143.37.0HVL0.050.00000UE in Seminoma
115Low molecular weight phosphotyrosine protein phosphatase isoform c47577148.70.3LVL0.050.00005UE in Seminoma
116Dynein heavy chain 8, axonemal isoform X1578811443132.36.3HVL0.050.00003UE in Seminoma
117Heat shock protein 75, mitochondrial isoform 1 precursor1557229838.30.3LVL0.050.00081UE in Seminoma
118Cullin-3 isoform 338071466558.32.3MVL0.050.00012UE in Seminoma
119Lysosomal alpha-glucosidase isoform X15304118635.00.3VLVL0.050.00074UE in Seminoma
120Isoleucine-tRNA ligase, mitochondrial precursor4685214740.71.7MVL0.050.00001UE in Seminoma
121Protein FAM71B22241863346.71.3MVL0.050.00050UE in Seminoma
122Actin-related protein T22989380845.71.7MVL0.060.00004UE in Seminoma
123Thioredoxin domain-containing protein 314883937218.31.0LVL0.060.00016UE in Seminoma
124Carnitine O-palmitoyltransferase 1, muscle isoform isoform a475805011.31.0LVL0.060.00107UE in Seminoma
125Phosphoglycolate phosphatase10879665315.30.3LVL0.060.00014UE in Seminoma
126Ecto-ADP-ribosyltransferase 3 isoform X853037770638.31.7MVL0.060.00004UE in Seminoma
127EF-hand calcium-binding domain-containing protein 1 isoform a1337578711.30.3LVL0.070.00341UE in Seminoma
128Izumo sperm-egg fusion protein 2 isoform X15788339329.00.3LVL0.070.00273UE in Seminoma
129Sodium/potassium-transporting ATPase subunit alpha-4 isoform 115394639759.75.3MVL0.070.00006UE in Seminoma
130Enoyl-CoA delta isomerase 2, mitochondrial isoform 226027483225.31.0MVL0.070.00081UE in Seminoma
131Casein kinase II subunit beta isoform 1235032959.30.3LVL0.070.00181UE in Seminoma
132Small membrane A-kinase anchor protein1103497429.30.3LVL0.070.00193UE in Seminoma
13360S ribosomal protein L12450659714.30.7LVL0.070.00044UE in Seminoma
134Leucine-rich repeat-containing protein 37A3 precursor7567761220.31.3MVL0.070.00021UE in Seminoma
135NADH dehydrogenase (ubiquinone) iron-sulfur protein 8, mitochondrial isoform X15303968188.00.3LVL0.070.00305UE in Seminoma
136Heat shock 70 protein 4L3154194193.32.3HVL0.080.00012UE in Seminoma
137Sperm equatorial segment protein 1 precursor21717832100.75.0HVL0.080.00000UE in Seminoma
138Pyruvate dehydrogenase E1 component subunit beta, mitochondrial isoform 1 precursor15656440367.33.3MVL0.080.00002UE in Seminoma
139Choline transporter-like protein 5 isoform B1942396338.01.3LVL0.080.00340UE in Seminoma
1406-Phosphofructokinase type C isoform 111321601131.310.7HL0.090.00000UE in Seminoma
14126S proteasome non-ATPase regulatory subunit 12 isoform 1450622110.70.7LVL0.090.00427UE in Seminoma
142ruvB-like 25730023137.37.7HVL0.090.00007UE in Seminoma
143T-complex protein 1 subunit gamma isoform a63162572128.77.7HVL0.090.00000UE in Seminoma
144ATP synthase subunit beta, mitochondrial precursor32189394354.321.7HM0.090.00000UE in Seminoma
145Phosphatidylglycerophosphatase and protein-tyrosine phosphatase 1 isoform 114822488411.70.7LVL0.090.00097UE in Seminoma
14626S proteasome non-ATPase regulatory subunit 32577761235.33.0MVL0.090.00001UE in Seminoma
147Importin-5 isoform X253042335024.71.7MVL0.100.00181UE in Seminoma
148Mitochondrial dicarboxylate carrier isoform 22014959856.03.7MVL0.100.00026UE in Seminoma
149TMEM189-UBE2V1 fusion protein408061908.30.7LVL0.100.00394UE in Seminoma
150Dynein heavy chain 7, axonemal15130112718.01.0LVL0.110.00033UE in Seminoma
151Lysozyme-like protein 1733901439.70.7LVL0.110.00451UE in Seminoma
152Importin subunit alpha-1450489754.73.3MVL0.110.00004UE in Seminoma
153Nuclear pore complex protein Nup155 isoform 12443014986.08.3HL0.120.00002UE in Seminoma
154Mitochondrial 2-oxoglutarate/malate carrier protein isoform 12136111439.02.7MVL0.120.00399UE in Seminoma
155Hyaluronidase PH-20 isoform 22351041835.32.3MVL0.120.00063UE in Seminoma
15640S ribosomal protein S16450669110.70.7LVL0.120.00186UE in Seminoma
15726S proteasome non-ATPase regulatory subunit 112887272513.01.0LVL0.120.00032UE in Seminoma
15826S proteasome non-ATPase regulatory subunit 6 isoform 2766191418.71.7LVL0.130.00236UE in Seminoma
159T-complex protein 1 subunit zeta-2 isoform X157883026736.73.3MVL0.130.00001UE in Seminoma
160Bifunctional ATP-dependent dihydroxyacetone kinase/FAD-AMP lyase (cyclizing) isoform X153039657629.03.0MVL0.130.00104UE in Seminoma
161Ropporin-1B5989140992.77.3HVL0.130.00003UE in Seminoma
162Dynactin subunit 2 isoform 338752797415.71.7LVL0.130.00423UE in Seminoma
163ras-related protein Rab-141992348319.01.3LVL0.130.00925UE in Seminoma
164Proteasome activator complex subunit 416364428352.75.7MVL0.130.00058UE in Seminoma
165T-complex protein 1 subunit alpha isoform a57863257132.313.0HL0.130.00002UE in Seminoma
166Pyruvate dehydrogenase E1 component subunit alpha, testis-specific form, mitochondrial precursor488554350.03.7MVL0.130.00018UE in Seminoma
167Dynein light chain roadblock-type 2187023238.70.7LVL0.130.00338UE in Seminoma
168Nuclear transport factor 250319859.70.7LVL0.130.00959UE in Seminoma
169Metalloreductase STEAP4 isoform 110081581513.31.7LVL0.130.00942UE in Seminoma
170Prenylated Rab acceptor protein 12221443098.31.0LVL0.130.00233UE in Seminoma
171Heat shock protein 105 isoform 1425441598.70.7LVL0.140.00595UE in Seminoma
172ATP synthase subunit gamma, mitochondrial isoform L (liver) precursor5034598848.73.3MVL0.140.00014UE in Seminoma
1733-Hydroxyisobutyryl-CoA hydrolase, mitochondrial isoform 1 precursor3759447111.71.0LVL0.140.00055UE in Seminoma
174Transmembrane protein 89 precursor5684763012.71.0LVL0.140.00529UE in Seminoma
175T-complex protein 1 subunit beta isoform 15453603120.712.0HL0.140.00005UE in Seminoma
176T-complex protein 1 subunit zeta isoform a450264371.77.3MVL0.150.00013UE in Seminoma
177Inactive serine protease 54 precursor12293742019.01.7LVL0.150.00060UE in Seminoma
178Nucleoporin p54 isoform 12605123721.72.3MVL0.160.01278UE in Seminoma
179T-complex protein 1 subunit theta isoform 14876293277.78.3ML0.160.00032UE in Seminoma
180Sperm protein associated with the nucleus on the X chromosome B/F19057019222.02.7MVL0.160.00428UE in Seminoma
181Histone H2A-Bbd type 2/36302993521.72.0MVL0.160.00688UE in Seminoma
182Transcription elongation factor B polypeptide 2 isoform a600589011.01.3LVL0.160.00017UE in Seminoma
183Protein MENT isoform X157880115097.711.0HL0.170.00005UE in Seminoma
184ATP synthase subunit d, mitochondrial isoform a545355933.03.0MVL0.170.00091UE in Seminoma
185Ropporin-1A isoform X153037481455.75.7MVL0.170.00001UE in Seminoma
186ATP synthase F (0) complex subunit B1, mitochondrial precursor2136156535.33.7MVL0.170.00076UE in Seminoma
187NADH dehydrogenase (ubiquinone) flavoprotein 1, mitochondrial isoform 1 precursor2014956814.01.7LVL0.170.00400UE in Seminoma
188Apolipoprotein O isoform X157883796140.34.3MVL0.170.00011UE in Seminoma
18926S proteasome non-ATPase regulatory subunit 1 isoform 12577760049.08.3ML0.170.00016UE in Seminoma
190Elongation factor 1-delta isoform 130455558132.33.7MVL0.180.00006UE in Seminoma
19126S proteasome non-ATPase regulatory subunit 815663100525.72.3MVL0.180.00001UE in Seminoma
192ATP synthase subunit alpha, mitochondrial isoform a precursor50345984265.333.0HM0.180.00001UE in Seminoma
193Heat shock 70 protein 1-like isoform X1530381921207.024.3HM0.190.00038UE in Seminoma
194Nitrilase homolog 1 isoform 329763234818.72.0LVL0.190.00095UE in Seminoma
195T-complex protein 1 subunit eta isoform a5453607129.716.0HL0.190.00010UE in Seminoma
196Calcium-binding tyrosine phosphorylation-regulated protein isoform a2479710863.39.0ML0.200.00012UE in Seminoma
197Tricarboxylate transport protein, mitochondrial isoform b37471734315.31.7LVL0.200.00049UE in Seminoma
198T-complex protein 1 subunit epsilon2430793978.711.3ML0.200.00001UE in Seminoma
199Tissue alpha-L-fucosidase precursor11936034819.01.7LVL0.200.00008UE in Seminoma
200GTP-binding nuclear protein Ran545355522.02.7MVL0.200.00007UE in Seminoma
201Dipeptidyl peptidase 2 isoform X153042672617.71.7LVL0.200.00216UE in Seminoma
2023’(2’),5’-Bisphosphate nucleotidase 1 isoform X353036593119.32.3LVL0.200.00871UE in Seminoma
203Lysine-tRNA ligase isoform 119427221030.03.0MVL0.200.00462UE in Seminoma
204Mitochondrial thiamine pyrophosphate carrier isoform X153041263016.32.0LVL0.210.00139UE in Seminoma
205Vesicle-fusing ATPase isoform X157883100716.72.3LVL0.210.00045UE in Seminoma
206FUN14 domain-containing protein 22437124860.38.0ML0.220.00023UE in Seminoma
207Mitochondrial pyruvate carrier 221952187225.75.0MVL0.220.00370UE in Seminoma
208Dynein light chain 1, axonemal isoform 116460715614.32.0LVL0.230.00000UE in Seminoma
209Cytochrome b-c1 complex subunit 2, mitochondrial precursor50592988111.014.0HL0.230.00006UE in Seminoma
210ADP/ATP translocase 413775208140.325.3HM0.230.00180UE in Seminoma
21126S protease regulatory subunit 7 isoform 145062099.71.7LVL0.230.00149UE in Seminoma
212Uncharacterized protein C9orf93328500645.06.7MVL0.230.00005UE in Seminoma
213ADP/ATP translocase 215607145935.78.3ML0.240.00081UE in Seminoma
214Synaptojanin-2-binding protein15738899328.35.0MVL0.240.00057UE in Seminoma
215Heat shock 70 protein 1A/1B16746617354.78.0ML0.240.00086UE in Seminoma
21626S protease regulatory subunit 6B isoform 1572999116.02.3LVL0.240.00222UE in Seminoma
217Mannose-6-phosphate isomerase isoform 145052359.01.3LVL0.250.00220UE in Seminoma
218Nuclear pore membrane glycoprotein 210 precursor2747713423.33.3MVL0.250.00026UE in Seminoma
219Arylsulfatase A isoform a precursor31356979128.03.3MVL0.250.00335UE in Seminoma
220Leucine-rich repeat-containing protein 37A isoform X5530413292165.727.7HM0.260.00002UE in Seminoma
221Solute carrier family 2, facilitated glucose transporter member 5 isoform X257879962131.07.7MVL0.260.00472UE in Seminoma
222Protein-glutamine gamma-glutamyltransferase 4156627577232.344.0HM0.260.00006UE in Seminoma
223Protein FAM162A493557219.01.3LVL0.260.00288UE in Seminoma
22426S protease regulatory subunit 6A2136114422.34.0MVL0.270.00780UE in Seminoma
225Myosin regulatory light chain 12B1580901611.72.3LVL0.270.00058UE in Seminoma
226Hexokinase-1 isoform X2530393498345.364.0HM0.270.00001UE in Seminoma
227NADH dehydrogenase (ubiquinone) iron-sulfur protein 7, mitochondrial1872816169.72.0LVL0.270.00101UE in Seminoma
228Cytochrome b-c1 complex subunit Rieske, mitochondrial16364432127.04.7MVL0.270.00004UE in Seminoma
229Leucine-rich repeat-containing protein 37B precursor53829385176.340.3HM0.270.00007UE in Seminoma
230ES1 protein homolog, mitochondrial-like isoform X157879778035.05.7MVL0.270.00001UE in Seminoma
231Lysosomal Pro-X carboxypeptidase isoform 1 preproprotein482694013.31.7LVL0.270.00077UE in Seminoma
232Transmembrane protein 190 precursor2104026333.35.7MVL0.280.00004UE in Seminoma
233UTP-glucose-1-phosphate uridylyltransferase isoform a4825596620.35.0MVL0.280.00603UE in Seminoma
23426S protease regulatory subunit 10B19553939521.34.3MVL0.290.00659UE in Seminoma
235Dynactin subunit 1 isoform 420527739621.73.7MVL0.290.00497UE in Seminoma
23626S protease regulatory subunit 8 isoform 12449743517.03.7LVL0.290.00479UE in Seminoma
237Ethanolamine-phosphate cytidylyltransferase isoform 653252497716.03.0LVL0.290.00018UE in Seminoma
23860 heat shock protein, mitochondrial isoform X1530370277125.716.3HL0.300.00029UE in Seminoma
239Beta-galactosidase-1-like protein isoform X153037095435.34.7MVL0.300.00099UE in Seminoma
240Adenylate kinase isoenzyme 1 isoform X153039069445.37.7MVL0.300.00114UE in Seminoma
241Dynein light chain Tctex-type 1573008510.01.7LVL0.300.00600UE in Seminoma
242Chitinase domain-containing protein 1 isoform X253039567017.33.3LVL0.310.00482UE in Seminoma
243A-kinase anchor protein 4 isoform 121493037156.328.0HM0.310.00000UE in Seminoma
244Hypoxia up-regulated protein 1 isoform X2530397761177.037.0HM0.310.00002UE in Seminoma
245Diablo homolog, mitochondrial isoform 1 precursor984529727.36.7MVL0.320.00223UE in Seminoma
246Zona pellucida-binding protein 2 isoform 2 precursor4055638945.79.0ML0.320.00009UE in Seminoma
247Ubiquitin-like modifier-activating enzyme 1 isoform X153042153975.011.3ML0.320.00035UE in Seminoma
24840S ribosomal protein S15a1416546912.72.3LVL0.330.00231UE in Seminoma
249Prohibitin isoform 152749827922.74.7MVL0.330.00192UE in Seminoma
250Long-chain-fatty-acid-CoA ligase 6 isoform e32741232739.06.0MVL0.330.00042UE in Seminoma
251Importin subunit beta-1 isoform 11992314254.711.7ML0.340.00045UE in Seminoma
252Long-chain-fatty-acid-CoA ligase 1 isoform X3530377352170.745.7HM0.340.00024UE in Seminoma
253AP-1 complex subunit beta-1 isoform b26043686012.02.3LVL0.340.00257UE in Seminoma
254Acrosin precursor148613878255.765.3HM0.340.00011UE in Seminoma
255Glutathione S-transferase omega-2 isoform 230036056710.32.0LVL0.340.00400UE in Seminoma
256Carboxypeptidase D isoform 1 precursor2220261136.37.0MVL0.340.02105UE in Seminoma
257Phosphate carrier protein, mitochondrial isoform b precursor450577538.314.0ML0.350.00176UE in Seminoma
258Heat shock 70 protein 43832703944.77.7MVL0.350.00303UE in Seminoma
259Fatty acid-binding protein, epidermal455758130.76.0MVL0.350.00328UE in Seminoma
260Ras-related protein Rab-2A isoform a4506365156.737.3HM0.360.00002UE in Seminoma
2613-hydroxyacyl-CoA dehydrogenase type-2 isoform 1475850443.09.3ML0.360.00138UE in Seminoma
262T-complex protein 1 subunit delta isoform a38455427108.325.7HM0.360.00075UE in Seminoma
263cAMP-dependent protein kinase type II-alpha regulatory subunit isoform X1530372834109.729.0HM0.360.00000UE in Seminoma
264Glutamine synthetase isoform X157880082823.35.3MVL0.360.01626UE in Seminoma
265Calmodulin isoform X157882614475.020.7MM0.370.00004UE in Seminoma
266Elongation factor 1-beta450347710.02.3LVL0.370.00022UE in Seminoma
267ruvB-like 1450675399.720.3HM0.370.00684UE in Seminoma
268Elongation factor 1-alpha 14503471155.051.3HM0.380.00001UE in Seminoma
269hsc70-interacting protein isoform 11992319330.37.3MVL0.380.01230UE in Seminoma
270Transmembrane protein 126A isoform 11415001722.06.0MVL0.380.00020UE in Seminoma
27126S proteasome non-ATPase regulatory subunit 2 isoform 12577760256.09.0ML0.390.00049UE in Seminoma
272Arachidonate 15-lipoxygenase B isoform d8506750123.74.3MVL0.400.00236UE in Seminoma
273NADH dehydrogenase (ubiquinone) 1 alpha subcomplex subunit 9, mitochondrial precursor66817649.72.3LVL0.400.00078UE in Seminoma
274electron transfer flavoprotein subunit beta isoform 1450360922.05.0MVL0.410.00000UE in Seminoma
275Tubulin alpha-3C/D chain156564363242.360.7HM0.410.00001UE in Seminoma
276Fumarylacetoacetate hydrolase domain-containing protein 2B4078639431.07.7MVL0.410.00018UE in Seminoma
277Peroxiredoxin-5, mitochondrial isoform a precursor691223878.020.7MM0.410.00039UE in Seminoma
278NADH-ubiquinone oxidoreductase 75 subunit, mitochondrial isoform 431698315621.04.0MVL0.420.03074UE in Seminoma
279Probable C-mannosyltransferase DPY19L2 isoform X1578823598101.026.0HM0.420.00052UE in Seminoma
280L-lactate dehydrogenase A-like 6B15082234145.042.7HM0.420.00021UE in Seminoma
281Acrosin-binding protein precursor17999524288.374.7HM0.430.00003UE in Seminoma
282Tubulin beta-4B chain5174735287.381.3HL0.430.00004UE in Seminoma
283Electron transfer flavoprotein subunit alpha, mitochondrial isoform a450360746.012.0ML0.440.00065UE in Seminoma
284Serpin B6 isoform d42587676879.033.3MM0.460.00013UE in Seminoma
285Lysozyme-like protein 4 isoform X257880563329.38.0ML0.460.00114UE in Seminoma
286cAMP-dependent protein kinase type I-alpha regulatory subunit isoform a44349796442.012.0ML0.470.00245UE in Seminoma
287Vesicle-associated membrane protein-associated protein A isoform 29472125238.712.0ML0.470.00220UE in Seminoma
288Acrosomal protein SP-10 isoform a precursor450187964.320.0MM0.480.00064UE in Seminoma
289Carnitine O-acetyltransferase isoform 238320967341.011.7ML0.480.00294UE in Seminoma
290Endoplasmin precursor4507677543.7146.0HH0.490.00066UE in Seminoma
291Izumo sperm-egg fusion protein 4 isoform 1 precursor89903025119.339.0HM0.530.00058UE in Seminoma
292Heat shock-related 70 protein 213676857442.0126.0HH0.530.00000UE in Seminoma
293Elongation factor 2450348384.330.0HM0.560.00021UE in Seminoma
294Clathrin heavy chain 1 isoform X2530411491122.751.3HM0.580.00014UE in Seminoma
295Sperm acrosome membrane-associated protein 1 precursor13569934176.083.7HH0.600.00073UE in Seminoma
296Zona pellucida-binding protein 1 isoform 1 precursor229577313278.7110.3HH0.610.00002UE in Seminoma
297Phosphoglycerate kinase 231543397204.379.0HM0.650.00034UE in Seminoma
2982,4-Dienoyl-CoA reductase, mitochondrial precursor4503301180.770.0HM0.650.00211UE in Seminoma
299Aminopeptidase N isoform X1530407092218.0186.3HH1.540.00040OE in Seminoma
300Calreticulin precursor4757900125.0106.7HH1.550.00511OE in Seminoma
301Dipeptidyl peptidase 418765694138.0122.0HH1.610.00164OE in Seminoma
302Plastin-2 isoform X2530402335116.7100.0HH1.620.00036OE in Seminoma
303Angiotensin-converting enzyme isoform 1 precursor4503273141.3124.7HH1.620.01310OE in Seminoma
304Transitional endoplasmic reticulum ATPase6005942145.097.0HH1.750.00238OE in Seminoma
305Neprilysin11625632785.359.3HH2.010.00052OE in Seminoma
306Adipocyte plasma membrane-associated protein2430820154.066.7MM2.010.00011OE in Seminoma
307Carboxypeptidase Z isoform 1 precursor6238887729.328.0MM2.060.00040OE in Seminoma
308Annexin A5450210741.048.0MM2.080.00049OE in Seminoma
309Annexin A2 isoform 25084538646.757.7MM2.090.00126OE in Seminoma
310Lysosome-associated membrane glycoprotein 1 precursor11238062818.020.0LM2.140.00275OE in Seminoma
311Plasma serine protease inhibitor preproprotein19401847240.745.7MM2.150.00208OE in Seminoma
312Dehydrogenase/reductase SDR family member 7 isoform X153040397822.335.7MM2.460.00033OE in Seminoma
313Cysteine-rich secretory protein 1 isoform 1 precursor2512198224.035.7MM2.530.00587OE in Seminoma
314Annexin A4450210522.331.3MM2.560.01438OE in Seminoma
315Calnexin precursor6693300534.351.3MM2.560.00094OE in Seminoma
316Clusterin isoform X1578815184116.7175.3HH2.710.00034OE in Seminoma
317Gastricsin isoform 1 preproprotein450575718.029.7LM2.760.00296OE in Seminoma
318Metalloproteinase inhibitor 1 precursor45075099.314.7LL2.800.00553OE in Seminoma
319Lactotransferrin isoform 1 precursor54607120702.3996.7HH2.870.00000OE in Seminoma
320Protein S100-A9450677323.745.0MM3.350.00011OE in Seminoma
321Glyceraldehyde-3-phosphate dehydrogenase, testis-specific765711648.7106.7MH3.410.00000OE in Seminoma
322Protein disulfide-isomerase precursor2007012585.0185.0HH3.530.00012OE in Seminoma
323Histone H4450430113.727.7LM3.560.00040OE in Seminoma
324Maltase-glucoamylase, intestinal isoform X157881472416.733.0LM3.580.00342OE in Seminoma
325Alpha-actinin-41202567844.048.7MM3.620.00001OE in Seminoma
326Lysozyme C precursor45578947.716.3VLL3.760.00087OE in Seminoma
327Alpha-1-antichymotrypsin precursor5065908018.733.7LM3.820.00044OE in Seminoma
328Protein S100-A82161454415.033.3LM3.980.00483OE in Seminoma
329Thioredoxin-dependent peroxide reductase, mitochondrial isoform b324833773.38.3VLL4.380.00328OE in Seminoma
330Semenogelin-2 precursor4506885261.3682.7HH4.410.00044OE in Seminoma
331Prosaposin isoform a preproprotein1138614720.048.0MM4.730.00704OE in Seminoma
332Olfactomedin-4 precursor3231359315.335.7LM4.900.00039OE in Seminoma
333Lactadherin isoform a preproprotein1678304758.325.0LM4.910.00144OE in Seminoma
334Mucin-5B precursor30117275022.065.0MM4.970.00001OE in Seminoma
335Prolactin-inducible protein precursor4505821238.3849.0HH4.990.00045OE in Seminoma
336Alpha-1-antitrypsin precursor18916352813.734.7LM5.010.00000OE in Seminoma
337Histone H3.348853855.718.7VLL5.700.00001OE in Seminoma
338Annexin A11 isoform X15303935084.016.0VLL6.080.00010OE in Seminoma
339Ectonucleotide pyrophosphatase/phosphodiesterase family member 31111602967.024.3VLM6.240.00214OE in Seminoma
340Cathepsin D preproprotein45031433.311.7VLL6.460.00352OE in Seminoma
341BPI fold-containing family B member 1 precursor408074824.715.3VLL6.640.00033OE in Seminoma
342Fibronectin isoform 1 preproprotein47132557112.7505.0HH7.150.00001OE in Seminoma
343Nucleobindin-2 isoform X157882055413.051.3LM7.440.00026OE in Seminoma
344Semenogelin-1 preproprotein450688394.0422.3HH7.780.00187OE in Seminoma
345Cytoskeleton-associated protein 4199203171.38.0VLL8.240.00084OE in Seminoma
346Ribonuclease pancreatic precursor382016840.74.7VLVL8.790.00074OE in Seminoma
347Transketolase isoform 12052774633.715.3VLL8.840.00097OE in Seminoma
348Neutrophil defensin 1 precursor1242485168.736.0LM9.320.00010OE in Seminoma
349Neutrophil gelatinase-associated lipocalin precursor384554029.358.7LM9.970.00000OE in Seminoma
350Myeloperoxidase precursor455775969.3368.7MH10.300.00000OE in Seminoma
351Myeloblastin precursor713616886.034.0VLM10.330.00005OE in Seminoma
352Catalase45570141.78.3VLL10.410.00009OE in Seminoma
353Azurocidin preproprotein1134267015.795.0LH11.520.00000OE in Seminoma
354Carcinoembryonic antigen-related cell adhesion molecule 1 isoform 1 precursor199231952.014.0VLL12.420.00321OE in Seminoma
355Erythrocyte band 7 integral membrane protein isoform a380169119.358.7LM13.460.00055OE in Seminoma
356Apolipoprotein B-100 precursor1059905321.712.0VLL13.650.00031OE in Seminoma
357Cysteine-rich secretory protein 3 isoform 1 precursor3002445600.75.3VLVL14.120.00098OE in Seminoma
358Mucin-6 isoform X15788409553.729.3VLM14.300.00214OE in Seminoma
359ERO1-like protein alpha precursor76570690.78.7VLL15.450.00087OE in Seminoma
360Annexin A348266434.045.7VLM17.620.00001OE in Seminoma
361Neutrophil elastase preproprotein45035492.323.0VLM17.840.00006OE in Seminoma
362Phospholipase B-like 1 precursor1102275981.722.7VLM22.140.00036OE in Seminoma
363Laminin subunit alpha-5 precursor212646024.339.0VLM22.300.00613OE in Seminoma
364Moesin isoform X15304217530.34.0VLVL25.180.00003OE in Seminoma
365Eosinophil cationic protein precursor452435071.020.3VLM27.030.00057OE in Seminoma
366Carcinoembryonic antigen-related cell adhesion molecule 6 precursor402550132.024.3VLM27.080.00170OE in Seminoma
367Syntenin-1 isoform X15303885180.35.7VLVL30.170.00085OE in Seminoma
368CD63 antigen isoform A3838724471.014.7VLL31.840.00518OE in Seminoma
369Collagen alpha-1 (XVIII) chain isoform 1 precursor1106112351.027.0VLM33.620.00154OE in Seminoma
370Laminin subunit gamma-1 precursor1453093261.022.0VLM40.700.00062OE in Seminoma
371Integrin alpha-M isoform 1 precursor2248312395.3176.0VLH50.910.00002OE in Seminoma
372Laminin subunit beta-2 isoform X15303724421.345.0VLM61.080.00000OE in Seminoma
373Alpha-1-acid glycoprotein 1 precursor1678577900.720.7VLM64.680.00005OE in Seminoma
374Integrin beta-2 precursor1885956772.3124.0VLH71.240.00000OE in Seminoma
375Carcinoembryonic antigen-related cell adhesion molecule 8 precursor213146000.318.0VLL103.730.00001OE in Seminoma
376Cytochrome b-245 heavy chain69960210.315.0VLL112.040.00002OE in Seminoma
377Bactericidal permeability-increasing protein precursor1572765990.349.0VLM300.570.00002OE in Seminoma
378Matrix metalloproteinase-9 preproprotein742722870.090.0niHSeminoma only0.00000Unique to Seminoma
379Leukocyte elastase inhibitor134890870.023.0niMSeminoma only0.00006Unique to Seminoma
380Arachidonate 5-lipoxygenase isoform 23718775250.012.7niLSeminoma only0.00000Unique to Seminoma
381Prostate and testis expressed protein 4 precursor2215545300.08.0niLSeminoma only0.00002Unique to Seminoma
382Chitinase-3-like protein 1 precursor1442262510.010.3niLSeminoma only0.00003Unique to Seminoma
383ADP-ribosyl cyclase 2 precursor1682291590.013.7niLSeminoma only0.00009Unique to Seminoma
384Peptidoglycan recognition protein 1 precursor48270360.010.7niLSeminoma only0.00059Unique to Seminoma
385Neutrophil collagenase preproprotein45052210.016.3niLSeminoma only0.00120Unique to Seminoma
386Haptoglobin isoform 2 preproprotein1869102960.011.3niLSeminoma only0.00207Unique to Seminoma
387Resistin precursor3011291800.06.0niVLSeminoma only0.00001Unique to Seminoma
388Matrilin-2 isoform a precursor625488600.03.0niVLSeminoma only0.00002Unique to Seminoma
389Immunoglobulin alpha Fc receptor isoform a precursor45036730.03.7niVLSeminoma only0.00018Unique to Seminoma
390Vascular non-inflammatory molecule 2 isoform X15788130450.06.0niVLSeminoma only0.00025Unique to Seminoma
391Integrin beta-2 isoform X15788365360.06.3niVLSeminoma only0.00029Unique to Seminoma
392Flotillin-2 isoform X15304109710.06.3niVLSeminoma only0.00055Unique to Seminoma
393Cathepsin G preproprotein45031490.03.3niVLSeminoma only0.00065Unique to Seminoma

H: high; L: low; M: medium; ni: not identified; NSAF: normalized spectral abundance factor; OE: overexpressed; SC: spectral counts; UE: underexpressed; VL: very low

Table 2

Specific functions of the differentially expressed proteins related to reproductive system development and function identified by the bioinformatic analysis when comparing the sperm proteome of patients with testicular cancer seminoma with fertile men

ProcessProteinP
Binding of spermACE, ACR, CCT3, SPA17<0.0001
FertilizationACE, ACR, ATP1A4, SPA17<0.0001
Cell movement of spermATP1A4<0.0001
SpermatogenesisACE, ATP1A4, HSPA2, PSME4, SPA170.0003
Function of spermATP1A40.0028
Acrosome reactionACR0.0037
FertilityACE, ACR, PSME40.0067
Morphology of male germ cellsACR, PSME40.0089
Morphology of spermACR0.0120
Hyperactivation of spermATP1A40.0133

ACE: angiotensin-converting enzyme; ACR: acrosin precursor; ATP1A4: sodium/potassium-transporting ATPase subunit alpha-4; CCT3: T-complex protein 1 subunit gamma; HSPA2: heat shock-related 70 kDa protein 2; PSME4: proteasome activator complex subunit 4; SPA17: sperm surface protein Sp17

Table 3

Proteomic data of the differentially expressed proteins identified in the spermatozoa samples of fertile men (control) and men with testicular cancer seminoma before cancer therapy, which were selected for validation by western blot

ProteinAbundanceNSAF ratioExpression profileP

ControlSeminoma
ACEHighHigh1.62Overexpressed in seminoma0.0131
ACRHighMedium0.34Underexpressed in seminoma0.0001
ATP1A4MediumVery low0.07Underexpressed in seminoma0.0001
ATP5A1HighMedium0.18Underexpressed in seminoma<0.0001
CCT3HighVery low0.09Underexpressed in seminoma<0.0001
HSPA2HighHigh0.53Underexpressed in seminoma<0.0001
NDUFS1MediumVery low0.42Underexpressed in seminoma0.0307
PSME4MediumVery low0.13Underexpressed in seminoma0.0006
SPA17MediumVery low0.02Underexpressed in seminoma0.0001
UQCRC2HighLow0.23Underexpressed in seminoma0.0001

ACE: angiotensin-converting enzyme; ACR: acrosin; ATP1A4: sodium/potassium-transporting ATPase subunit alpha-4; ATP5A: ATP synthase subunit alpha; CCT3: T-complex protein 1 subunit gamma; HSPA2: heat shock-related 70 kDa protein 2; NDUFS1: NADH-ubiquinone oxidoreductase 75 kDa subunit; NSAF: normalized spectral abundance factor; PSME4: proteasome activator complex subunit 4; SPA17: sperm surface protein Sp17; UQCRC2: cytochrome b-c1 complex subunit 2

  46 in total

Review 1.  Proteomic insights into the maturation and capacitation of mammalian spermatozoa.

Authors:  Mark A Baker; Brett Nixon; Nenad Naumovski; R John Aitken
Journal:  Syst Biol Reprod Med       Date:  2012-08       Impact factor: 3.061

Review 2.  Sperm proteomics: potential impact on male infertility treatment.

Authors:  Ashok Agarwal; Ricardo Pimenta Bertolla; Luna Samanta
Journal:  Expert Rev Proteomics       Date:  2016       Impact factor: 3.940

Review 3.  Supramolecular structure of the mitochondrial oxidative phosphorylation system.

Authors:  Egbert J Boekema; Hans-Peter Braun
Journal:  J Biol Chem       Date:  2006-11-13       Impact factor: 5.157

4.  Twenty years experience with semen cryopreservation in testicular cancer patients: who needs it?

Authors:  H Magelssen; T B Haugen; V von Düring; K K Melve; B Sandstad; S D Fosså
Journal:  Eur Urol       Date:  2005-11       Impact factor: 20.096

5.  Activity of testis angiotensin converting enzyme (ACE) in ejaculated human spermatozoa.

Authors:  H Shibahara; M Kamata; J Hu; H Nakagawa; H Obara; N Kondoh; H Shima; I Sato
Journal:  Int J Androl       Date:  2001-10

Review 6.  New insights into the t-complex and control of sperm function.

Authors:  L R Fraser; K Dudley
Journal:  Bioessays       Date:  1999-04       Impact factor: 4.345

7.  Expression of the rabbit sperm protein Sp17 in COS cells and interaction of recombinant Sp17 with the rabbit zona pellucida.

Authors:  N Yamasaki; R T Richardson; M G O'Rand
Journal:  Mol Reprod Dev       Date:  1995-01       Impact factor: 2.609

8.  Release of angiotensin-converting enzyme (ACE) from human spermatozoa during capacitation and acrosome reaction.

Authors:  F M Köhn; W Miska; W B Schill
Journal:  J Androl       Date:  1995 May-Jun

9.  Essential requirement for both hsf1 and hsf2 transcriptional activity in spermatogenesis and male fertility.

Authors:  Guanghu Wang; Zhekang Ying; Xiongjie Jin; Naxin Tu; Yan Zhang; Michele Phillips; Demetrius Moskophidis; Nahid F Mivechi
Journal:  Genesis       Date:  2004-02       Impact factor: 2.487

10.  Fertility after testicular cancer treatments: results of a large multicenter study.

Authors:  Eric Huyghe; Tomohiro Matsuda; Myriam Daudin; Christine Chevreau; Jean-Marc Bachaud; Pierre Plante; Louis Bujan; Patrick Thonneau
Journal:  Cancer       Date:  2004-02-15       Impact factor: 6.860

View more
  9 in total

Review 1.  Molecular Interactions Associated with Oxidative Stress-Mediated Male Infertility: Sperm and Seminal Plasma Proteomics.

Authors:  Manesh Kumar Panner Selvam; Damayanthi Durairajanayagam; Suresh C Sikka
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

2.  Effect of Malignancy on Semen Parameters.

Authors:  Guy Shrem; Liat Azani; Ido Feferkorn; Tamar Listovsky; Sofia Hussaini; Benjamin Farber; Michael H Dahan; Mali Salmon-Divon
Journal:  Life (Basel)       Date:  2022-06-20

Review 3.  Current Insights and Latest Updates in Sperm Motility and Associated Applications in Assisted Reproduction.

Authors:  Reyon Dcunha; Reda S Hussein; Hanumappa Ananda; Sandhya Kumari; Satish Kumar Adiga; Nagarajan Kannan; Yulian Zhao; Guruprasad Kalthur
Journal:  Reprod Sci       Date:  2020-12-07       Impact factor: 3.060

Review 4.  Proteomic Analyses of Human Sperm Cells: Understanding the Role of Proteins and Molecular Pathways Affecting Male Reproductive Health.

Authors:  Ashok Agarwal; Manesh Kumar Panner Selvam; Saradha Baskaran
Journal:  Int J Mol Sci       Date:  2020-02-27       Impact factor: 5.923

Review 5.  Semen quality from patients affected by seminomatous and non-seminomatous testicular tumor.

Authors:  Rosana Xavier; Renata Cristina de Carvalho; Renato Fraietta
Journal:  Int Braz J Urol       Date:  2021 May-Jun       Impact factor: 1.541

Review 6.  Proteostasis in the Male and Female Germline: A New Outlook on the Maintenance of Reproductive Health.

Authors:  Shenae L Cafe; Brett Nixon; Heath Ecroyd; Jacinta H Martin; David A Skerrett-Byrne; Elizabeth G Bromfield
Journal:  Front Cell Dev Biol       Date:  2021-04-16

7.  In Silico Sperm Proteome Analysis to Investigate DNA Repair Mechanisms in Varicocele Patients.

Authors:  Renata Finelli; Sara Darbandi; Peter Natesan Pushparaj; Ralf Henkel; Edmund Ko; Ashok Agarwal
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-17       Impact factor: 5.555

Review 8.  Testis-Specific Isoform of Na+-K+ ATPase and Regulation of Bull Fertility.

Authors:  Saurabh Tiwari; Gayathri Rajamanickam; Veena Unnikrishnan; Mina Ojaghi; John P Kastelic; Jacob C Thundathil
Journal:  Int J Mol Sci       Date:  2022-07-19       Impact factor: 6.208

9.  Distinct Proteomic Profile of Spermatozoa from Men with Seminomatous and Non-Seminomatous Testicular Germ Cell Tumors.

Authors:  Manesh Kumar Panner Selvam; Marco G Alves; Tânia R Dias; Peter N Pushparaj; Ashok Agarwal
Journal:  Int J Mol Sci       Date:  2020-07-08       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.